Similarities in features of autism and asthma and a possible link to acetaminophen use

Medical Hypotheses

Volumn 74, Issue 1, 2010, Pages 7-11

  Becker, Kevin G ^a   Schultz, Stephen T ^b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARACETAMOL;

ARTICLE; ASTHMA; AUTISM; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG MECHANISM; DRUG OVERDOSE; EVIDENCE BASED MEDICINE; FEVER; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MAST CELL; PAIN; PREVALENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ACETAMINOPHEN; ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNITY, INNATE; INFANT; INFANT, NEWBORN; MACROPHAGES; MAST CELLS; MODELS, BIOLOGICAL; MODELS, THEORETICAL;

EID: 70549097126     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.08.033     Document Type: Article

References (84)

1. Heuer L., Ashwood P., Schauer J., Goines P., Krakowiak P., Hertz-Picciotto I., et al. Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms. Autism Res 1 5 (2008) 275-283
2. Li X., Chauhan A., Sheikh A.M., Patil S., Chauhan V., Li X.M., et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol 207 1-2 (2009) 111-116
3. Enstrom A., Krakowiak P., Onore C., Pessah I.N., Hertz-Picciotto I., Hansen R.L., et al. Increased IgG4 levels in children with autism disorder. Brain Behav Immun 23 3 (2009) 389-395
4. Molloy C.A., Morrow A.L., Meinzen-Derr J., Schleifer K., Dienger K., Manning-Courtney P., et al. Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol 172 1-2 (2006) 198-205
5. Wills S., Cabanlit M., Bennett J., Ashwood P., Amaral D.G., and Van de Water J. Detection of autoantibodies to neural cells of the cerebellum in the plasma of subjects with autism spectrum disorders. Brain Behav Immun 23 1 (2009) 64-74
6. Zimmerman A.W., Jyonouchi H., Comi A.M., Connors S.L., Milstien S., Varsou A., et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol 33 3 (2005) 195-201
7. Ashwood P., and Wakefield A.J. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Neuroimmunol 173 1-2 (2006) 126-134
8. Vargas D.L., Nascimbene C., Krishnan C., Zimmerman A.W., and Pardo C.A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 57 1 (2005) 67-81
9. Elder L.M., Dawson G., Toth K., Fein D., and Munson J. Head circumference as an early predictor of autism symptoms in younger siblings of children with autism spectrum disorder. J Autism Dev Disord 38 6 (2008) 1104-1111
10. Weizman A., Weizman R., Szekely G.A., Wijsenbeek H., and Livni E. Abnormal immune response to brain tissue antigen in the syndrome of autism. Am J Psychiatry 139 11 (1982) 1462-1465
11. Theoharides T.C., and Doyle R. Autism, gut-blood-brain barrier, and mast cells. J Clin Psychopharmacol 28 5 (2008) 479-483
12. Enstrom A.M., Onore C.E., Water J.A., and Ashwood P. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immun (2009)
13. Comi A.M., Zimmerman A.W., Frye V.H., Law P.A., and Peeden J.N. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol 14 6 (1999) 388-394
14. Molloy C.A., Morrow A.L., Meinzen-Derr J., Dawson G., Bernier R., Dunn M., et al. Familial autoimmune thyroid disease as a risk factor for regression in children with autism spectrum disorder: a CPEA study. J Autism Dev Disord 36 3 (2006) 317-324
15. Atladottir H.O., Pedersen M.G., Thorsen P., Mortensen P.B., Deleuran B., Eaton W.W., et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics (2009)
16. Becker K.G. Autism, asthma, inflammation, and the hygiene hypothesis. Med Hypotheses 69 4 (2007) 731-740
17. Enstrom A.M., Van de Water J.A., and Ashwood P. Autoimmunity in autism. Curr Opin Invest Drugs 10 5 (2009) 463-473
18. Castellani M.L., Conti C.M., Kempuraj D.J., Salini V., Vecchiet J., Tete S., et al. Autism and immunity: revisited study. Int J Immunopathol Pharmacol 22 1 (2009) 15-19
19. Ashwood P., Wills S., and Van de Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol 80 1 (2006) 1-15
20. Torres A.R. Is fever suppression involved in the etiology of autism and neurodevelopmental disorders?. BMC Pediatr 3 (2003) 9
21. Curran L.K., Newschaffer C.J., Lee L.C., Crawford S.O., Johnston M.V., and Zimmerman A.W. Behaviors associated with fever in children with autism spectrum disorders. Pediatrics 120 6 (2007) e1386-e1392
22. Schultz S. Autism risk (2008), VDM Verlag Dr. Müller Aktiengesellschaft & Co., Saarbrücken, Germany
23. Folstein S.E., and Rosen-Sheidley B. Genetics of autism: complex aetiology for a heterogeneous disorder. Nat Rev Genet 2 12 (2001) 943-955
24. Thomson A.W., Turnquist H.R., and Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9 5 (2009) 324-337
25. Kim M.S., Radinger M., and Gilfillan A.M. The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol 29 10 (2008) 493-501
26. Gunzl P., and Schabbauer G. Recent advances in the genetic analysis of PTEN and PI3K innate immune properties. Immunobiology 213 9-10 (2008) 759-765
27. Varga E.A., Pastore M., Prior T., Herman G.E., and McBride K.L. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet Med 11 2 (2009) 111-117
28. Page D.T., Kuti O.J., Prestia C., and Sur M. Haploinsufficiency for PTEN and serotonin transporter cooperatively influences brain size and social behavior. Proc Natl Acad Sci USA 106 6 (2009) 1989-1994
29. Campbell D.B., Sutcliffe J.S., Ebert P.J., Militerni R., Bravaccio C., Trillo S., et al. A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci USA 103 45 (2006) 16834-16839
30. Sousa I., Clark T.G., Toma C., Kobayashi K., Choma M., Holt R., et al. MET and autism susceptibility: family and case-control studies. Eur J Hum Genet 17 6 (2009) 749-758
31. McCall-Culbreath K.D., Li Z., and Zutter M.M. Crosstalk between the alpha2beta1 integrin and c-met/HGF-R regulates innate immunity. Blood 111 7 (2008) 3562-3570
32. Campbell D.B., Li C., Sutcliffe J.S., Persico A.M., and Levitt P. Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder. Autism Res 1 3 (2008) 159-168
33. Rogers A.J., Raby B.A., Lasky-Su J.A., Murphy A., Lazarus R., Klanderman B.J., et al. Assessing the reproducibility of asthma candidate gene associations, using genome-wide data. Am J Respir Crit Care Med 179 12 (2009) 1084-1090
34. Cunningham O., Campion S., Perry V.H., Murray C., Sidenius N., Docagne F., et al. Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation. Glia (2009)
35. Sillaber C., Baghestanian M., Hofbauer R., Virgolini I., Bankl H.C., Fureder W., et al. Molecular and functional characterization of the urokinase receptor on human mast cells. J Biol Chem 272 12 (1997) 7824-7832
36. Ma Z., Paek D., and Oh C.K. Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation. Clin Exp Allergy (2009)
37. Brooks A.M., Bates M.E., Vrtis R.F., Jarjour N.N., Bertics P.J., and Sedgwick J.B. Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma. Am J Respir Cell Mol Biol 35 4 (2006) 503-511
38. Weiss L.A., Kosova G., Delahanty R.J., Jiang L., Cook E.H., Ober C., et al. Variation in ITGB3 is associated with whole-blood serotonin level and autism susceptibility. Eur J Hum Genet 14 8 (2006) 923-931
39. Thompson E.E., Pan L., Ostrovnaya I., Weiss L.A., Gern J.E., Lemanske Jr. R.F., et al. Integrin beta 3 genotype influences asthma and allergy phenotypes in the first 6 years of life. J Allergy Clin Immunol 119 6 (2007) 1423-1429
40. Columbo M., and Bochner B.S. Human skin mast cells adhere to vitronectin via the alphavbeta3 integrin receptor (CD51/CD61). J Allergy Clin Immunol 107 3 (2001) 554
41. Castells M.C., Klickstein L.B., Hassani K., Cumplido J.A., Lacouture M.E., Austen K.F., et al. Gp49B1-alpha(v)beta3 interaction inhibits antigen-induced mast cell activation. Nat Immunol 2 5 (2001) 436-442
42. Jakus Z., Fodor S., Abram C.L., Lowell C.A., and Mocsai A. Immunoreceptor-like signaling by beta 2 and beta 3 integrins. Trends Cell Biol 17 10 (2007) 493-501
43. Cheslack-Postava K., Fallin M.D., Avramopoulos D., Connors S.L., Zimmerman A.W., Eberhart C.G., et al. Beta2-Adrenergic receptor gene variants and risk for autism in the AGRE cohort. Mol Psychiatry 12 3 (2007) 283-291
44. Geschwind D.H., Sowinski J., Lord C., Iversen P., Shestack J., Jones P., et al. The autism genetic resource exchange: a resource for the study of autism and related neuropsychiatric conditions. Am J Hum Genet 69 2 (2001) 463-466
45. Connors S.L., Crowell D.E., Eberhart C.G., Copeland J., Newschaffer C.J., Spence S.J., et al. Beta2-adrenergic receptor activation and genetic polymorphisms in autism: data from dizygotic twins. J Child Neurol 20 11 (2005) 876-884
46. Litonjua A.A. The significance of beta2-adrenergic receptor polymorphisms in asthma. Curr Opin Pulm Med 12 1 (2006) 12-17
47. Renner P., Roger T., and Calandra T. Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. Clin Infect Dis 41 Suppl. 7 (2005) S513-S519
48. Bacher M., Metz C.N., Calandra T., Mayer K., Chesney J., Lohoff M., et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93 15 (1996) 7849-7854
49. Grigorenko E.L., Han S.S., Yrigollen C.M., Leng L., Mizue Y., Anderson G.M., et al. Macrophage migration inhibitory factor and autism spectrum disorders. Pediatrics 122 2 (2008) e438-e445
50. Mizue Y., Ghani S., Leng L., McDonald C., Kong P., Baugh J., et al. Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci USA 102 40 (2005) 14410-14415
51. Rigante D., Flex A., Federico G., Pola R., Candelli M., Manna R., et al. Serum macrophage migration inhibitory factor (MIF) in the intercritical phase of hereditary periodic fevers and its relationship with the MIF-173G/C polymorphism. Scand J Rheumatol 36 4 (2007) 307-310
52. Senter P.D., Al-Abed Y., Metz C.N., Benigni F., Mitchell R.A., Chesney J., et al. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci USA 99 1 (2002) 144-149
53. Chun L.J., Tong M.J., Busuttil R.W., and Hiatt J.R. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol 43 4 (2009) 342-349
54. Masubuchi Y., Sugiyama S., and Horie T. Th1/Th2 cytokine balance as a determinant of acetaminophen-induced liver injury. Chem Biol Interact 179 2-3 (2009) 273-279
55. Yohe H.C., O'Hara K.A., Hunt J.A., Kitzmiller T.J., Wood S.G., Bement J.L., et al. Involvement of Toll-like receptor 4 in acetaminophen hepatotoxicity. Am J Physiol Gastrointest Liver Physiol 290 6 (2006) G1269-G1279
56. Sander L.E., and Blander J.M. Inflammasome and Toll-like receptor 9: partners in crime in toxic liver injury. Hepatology 49 6 (2009) 2119-2121
57. Wu M., Katta A., Gadde M.K., Liu H., Kakarla S.K., Fannin J., et al. Aging-associated dysfunction of Akt/protein kinase B: S-nitrosylation and acetaminophen intervention. PLoS One 4 7 (2009) e6430
58. Shaheen S.O., Sterne J.A., Songhurst C.E., and Burney P.G. Frequent paracetamol use and asthma in adults. Thorax 55 4 (2000) 266-270
59. Beasley R., Clayton T., Crane J., von Mutius E., Lai C.K., Montefort S., et al. Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6-7 years: analysis from phase three of the ISAAC programme. Lancet 372 9643 (2008) 1039-1048
60. Shaheen S.O., Newson R.B., Henderson A.J., Headley J.E., Stratton F.D., Jones R.W., et al. Prenatal paracetamol exposure and risk of asthma and elevated immunoglobulin E in childhood. Clin Exp Allergy 35 1 (2005) 18-25
61. Allmers H., Skudlik C., and John S.M. Acetaminophen use: a risk for asthma?. Curr Allergy Asthma Rep 9 2 (2009) 164-167
62. Eneli I., Sadri K., Camargo Jr. C., and Barr R.G. Acetaminophen and the risk of asthma: the epidemiologic and pathophysiologic evidence. Chest 127 2 (2005) 604-612
63. Schultz S.T., Klonoff-Cohen H.S., Wingard D.L., Akshoomoff N.A., Macera C.A., and Ji M. Acetaminophen (paracetamol) use, measles-mumps-rubella vaccination, and autistic disorder: the results of a parent survey. Autism 12 3 (2008) 293-307
64. Ballatori N., Krance S.M., Notenboom S., Shi S., Tieu K., and Hammond C.L. Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 390 3 (2009) 191-214
65. Bohanec Grabar P., Logar D., Tomsic M., Rozman B., and Dolzan V. Genetic polymorphisms of glutathione S-transferases and disease activity of rheumatoid arthritis. Clin Exp Rheumatol 27 2 (2009) 229-236
66. Chung Y.S., Cha H.E., Kang I.G., Hwang Y.J., and Kim S.T. Polymorphism at the glutathione S-transferase P1 locus in Korean patients with perennial allergic rhinitis. Am J Rhinol 20 6 (2006) 648-651
67. Bekris L.M., Shephard C., Peterson M., Hoehna J., Van Yserloo B., Rutledge E., et al. Glutathione-S-transferase M1 and T1 polymorphisms and associations with type 1 diabetes age-at-onset. Autoimmunity 38 8 (2005) 567-575
68. Rousar T., Parik P., Kucera O., Bartos M., and Cervinkova Z. Glutathione reductase is inhibited by acetaminophen-glutathione conjugate in vitro. Physiol Res (2009)
69. Geier D.A., Kern J.K., Garver C.R., Adams J.B., Audhya T., and Geier M.R. A prospective study of transsulfuration biomarkers in autistic disorders. Neurochem Res 34 2 (2009) 386-393
70. James S.J., Melnyk S., Jernigan S., Hubanks A., Rose S., and Gaylor D.W. Abnormal transmethylation/transsulfuration metabolism and DNA hypomethylation among parents of children with autism. J Autism Dev Disord 38 10 (2008) 1966-1975
71. Hertz-Picciotto I., and Delwiche L. The rise in autism and the role of age at diagnosis. Epidemiology 20 1 (2009) 84-90
72. Croen L.A., Grether J.K., Hoogstrate J., and Selvin S. The changing prevalence of autism in California. J Autism Dev Disord 32 3 (2002) 207-215
73. Akinbami L.J., and Schoendorf K.C. Trends in childhood asthma: prevalence, health care utilization, and mortality. Pediatrics 110 2 Pt 1 (2002) 315-322
74. Grinker R.R., and Leventhal B.L. Estimating the incidence of autism. Epidemiology 20 4 (2009) 622-623 (author reply 623-24)
75. Gergen P.J., and Weiss K.B. Changing patterns of asthma hospitalization among children: 1979-1987. JAMA 264 13 (1990) 1688-1692
76. Gurney J.G., Fritz M.S., Ness K.K., Sievers P., Newschaffer C.J., and Shapiro E.G. Analysis of prevalence trends of autism spectrum disorder in Minnesota. Arch Pediatr Adolesc Med 157 7 (2003) 622-627
77. Taylor B., Miller E., Farrington C.P., Petropoulos M.C., Favot-Mayaud I., Li J., et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 353 9169 (1999) 2026-2029
78. Gillberg C., Cederlund M., Lamberg K., and Zeijlon L. Brief report: "the autism epidemic". The registered prevalence of autism in a Swedish urban area. J Autism Dev Disord 36 3 (2006) 429-435
79. Control CfD. Surgeon General's Advisory on the use of salicytes and Reye's syndrome. CDC Morbidity, Mortality Weekly Report 1982;31:289-90.
80. Arrowsmith J.B., Kennedy D.L., Kuritsky J.N., and Faich G.A. National patterns of aspirin use and Reye syndrome reporting, United States, 1980-1985. Pediatrics 79 6 (1987) 858-863
81. wikkipedia.org. 30.07.09. 1982 Chicago Tylenol murders, ; 2009 [accessed 30.07.09].
82. Beck M ea. The Tylenol Scare. Newsweek, October 11 1982.
83. Koepp S. A hard decision to swallow. Acetaminophen's maker will dump capsules and promote safer "caplets". Time 1982, March 3 1986.
84. EPA APRotEDU. 2009. Exhibit 5-31 asthma prevalence in US children 0-17 years, 1980-2007, ; [accessed 30.07.09].